


Icotinib

03/20

ALTERNATE NAMES: BPI-2009; BPI-2009H; N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine; Conmana; (3-Ethynylphenyl)(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diazacyclododeca[b]naphthalen-4-yl)-amine; N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.0¹⁴,19]jicosa-1(12),13,15,17,19-pentaen-18-amine

CATALOG #: B3003-5 5 mg
B3003-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₂H₂₁N₃O₄

MOLECULAR WEIGHT: 391.4

CAS NUMBER: 610798-31-7

APPEARANCE: Solid

PURITY: 610798-31-7

SOLUBILITY: ~75 mg/ml in DMSO

DESCRIPTION: Icotinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC₅₀ of 5 nM. It blocks EGFR-mediated intracellular tyrosine phosphorylation with an IC₅₀ of 45 nM in the human epidermoid carcinoma A431 cell line and inhibits tumor cell proliferation. Icotinib shows potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug is well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Tan, F., Shen, X., Wang, D., et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. *Lung Cancer*. 76(2):177-82 (2012).

RELATED PRODUCTS:

Branerutinib (Cat. No. B2998)
 Zanubrutinib (Cat. No. B2512)
 Avapritinib (Cat. No. B2999)
 Allitinib (Cat. No. B3002)
 Avitinib (Cat. No. B2995)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*